Navigation Links
Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012

BOONTON, N.J., March 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company's senior management team will host a conference call and live audio webcast on Thursday, March 8, 2012 at 11 a.m. ET to discuss fourth quarter and full-year 2011 financial results.

Interested participants and investors may access the conference call at 11 a.m. ET by dialing 866-277-1181 (U.S./Canada) or 617-597-5358 (international); participant code 82583482.  An audio webcast can be accessed by logging on to the Investors and Media section under the Events tab of the Unigene web site,  

A telephonic replay of the call will be available for two weeks beginning at 2 p.m. ET on March 8.  Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 18902945. The webcast replay will remain available in the Investors section of the Unigene Laboratories web site for 30 days.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020  /

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
2. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
3. Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
4. Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
5. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
6. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
7. ARUP Laboratories Announces Creation of Business Innovations Division
8. City of Mason and Top Gun Sales Performance Announce $4 Million Investment In New Corporate Headquarters
9. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
10. Regeneron Announces March 2012 Investor Conference Presentations
11. MiMedx Group Announces 2011 Results
Post Your Comments:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
Breaking Biology News(10 mins):